| Literature DB >> 27553084 |
Hershna Patel1, Andreas Kukol2.
Abstract
Virtual screening is used in biomedical research to predict the binding affinity of a large set of small organic molecules to protein receptor targets. This report shows the development and evaluation of a novel yet straightforward attempt to improve this ranking in receptor-based molecular docking using a receptor-decoy strategy. This strategy includes defining a decoy binding site on the receptor and adjusting the ranking of the true binding-site virtual screen based on the decoy-site screen. The results show that by docking against a receptor-decoy site with Autodock Vina, improved Receiver Operator Characteristic Enrichment (ROCE) was achieved for 5 out of fifteen receptor targets investigated, when up to 15 % of a decoy site rank list was considered. No improved enrichment was seen for 7 targets, while for 3 targets the ROCE was reduced. The extent to which this strategy can effectively improve ligand prediction is dependent on the target receptor investigated.Entities:
Keywords: Adjusted ranking; Autodock Vina; Docking; Enrichment; Receptor-decoy; Virtual screening
Mesh:
Substances:
Year: 2016 PMID: 27553084 PMCID: PMC4994241 DOI: 10.1186/s12952-016-0058-8
Source DB: PubMed Journal: J Negat Results Biomed ISSN: 1477-5751
Fig. 1a Acetycholine esterase (Ache) receptor with binding site shown in red and decoy site in blue. b Detailed view of Ache binding site. c Detailed view of Ache decoy site
ROCE at 1 % of the binding site list considering top x% of the decoy site list
| Top % of decoy site list | ||||||
|---|---|---|---|---|---|---|
| Target | 0 | 10 | 15 | 20 | 30 | 50 |
| Comt | 33.4a | 39.0 | 39.0 | 39.0 | 39.0 | 39.0 |
| AchE | 1.0a | 1.0 | 3.0 | 3.0 | 2.0 | 3.03 |
| CDK2 | 14.3a | 23.6 | 29.7 | 23.6 | 29.7 | 14.3 |
| HIVrt | 9.4a | 13.1 | 13.1 | 9.0 | 13.1 | 18.0 |
| Pparg | 58.0a | 99.0 | 84.0 | 84.0 | 84.0 | 84.0 |
| FGFR1 | 0.0 | 0.0 | 0.9 | 0.9 | 0.9 | 0.9 |
| InhA | 14.6 | 5.3 | 5.3 | 5.3 | 2.5 | 0.0 |
| PR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.0 |
| RXRa | 212.4 | 212.4 | 212.4 | 88.5 | 47.2 | 88.5 |
| VEGFr2 | 10.2 | 2.9 | 2.9 | 2.9 | 1.4 | 1.4 |
| MR | 178.3 | 178.3 | 71.3 | 71.3 | 71.3 | 71.3 |
| Hsp90 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| AmpC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Trypsin | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 |
| Parp | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 | 11.9 |
aResults taken from ref [11]
ROCE at 2 % of the binding site list considering top x% of the decoy site list
| Top % of decoy site list | ||||||
|---|---|---|---|---|---|---|
| Target | 0 | 10 | 15 | 20 | 30 | 50 |
| Comt | 10.4a | 11.2 | 11.2 | 11.2 | 11.2 | 11.2 |
| AchE | 1.5a | 2.0 | 2.0 | 1.5 | 2.0 | 1.5 |
| CDK2 | 13.3a | 15.7 | 15.7 | 15.7 | 11.9 | 5.8 |
| HIVrt | 8.8a | 9.0 | 9.0 | 7.2 | 7.2 | 11.0 |
| Pparg | 35.8a | 58.0 | 54.0 | 58.0 | 50.0 | 44.0 |
| FGFR1 | 0.6 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 |
| InhA | 12.4 | 3.1 | 3.1 | 2.5 | 1.2 | 0.0 |
| PR | 0.0 | 0.0 | 0.0 | 0.0 | 1.9 | 4.0 |
| RXRa | 70.8 | 97.4 | 70.8 | 40.5 | 17.7 | 23.6 |
| VEGFr2 | 5.3 | 1.4 | 2.1 | 2.1 | 2.9 | 1.4 |
| MR | 62.4 | 42.8 | 29.7 | 20.4 | 20.4 | 3.6 |
| Hsp90 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.5 |
| AmpC | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Trypsin | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 |
| Parp | 5.1 | 3.2 | 7.1 | 7.1 | 7.1 | 9.4 |
aResults taken from ref [11]
Cavity analysis of binding sites and decoy sites for all targets using KVFinder [15]
| Binding site Cavities | Decoy site cavities | |||||
|---|---|---|---|---|---|---|
| Receptor | Number | Total Volume (Å3) | Total Area (Å2) | Number | Total Volume (Å3) | Total Area (Å2) |
| Comt | 1 | 29.8 | 45.7 | 1 | 12.3 | 20.3 |
| AchE | 3 | 249.3 | 333.8 | 2 | 85.5 | 124.9 |
| CDK2 | 4 | 134.0 | 178.3 | 1 | 10.6 | 15.8 |
| HIVrt | 5 | 92.1 | 138.7 | 1 | 241.3 | 240.1 |
| Pparg | 2 | 394.4 | 414.8 | 1 | 8.6 | 14.4 |
| FGFR1 | 2 | 49.0 | 70.2 | 1 | 21.0 | 30.6 |
| InhA | 2 | 1119.7 | 834.8 | 1 | 6.0 | 10.1 |
| PR | 2 | 21.4 | 35.0 | 1 | 18.1 | 28.4 |
| RXRa | 1 | 57.5 | 72.0 | 1 | 21.0 | 30.2 |
| Vegfr2 | 5 | 129.3 | 193.0 | 4 | 117.4 | 168.0 |
| MR | 2 | 54.4 | 78.1 | 1 | 23.5 | 35.6 |
| Hsp90 | 4 | 166.8 | 233.7 | 2 | 30.0 | 46.1 |
| ampC | 3 | 100.8 | 121.3 | 1 | 5.8 | 9.7 |
| trypsin | 1 | 9.7 | 14.8 | 3 | 79.9 | 121.8 |
| Parp | 1 | 538.3 | 482.4 | 1 | 9.9 | 16.6 |